NCT03375320 2026-06-03Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)Phase 3 Active not recruiting298 enrolled 14 charts 1 FDA
NCT04211337 2026-03-19LIBRETTO-531Eli Lilly and CompanyPhase 3 Active not recruiting291 enrolled 16 charts 1 FDA